"Lebrikizumab Improves EASI, Pruritus In Adults With Atopic Dermatitis" - Stacy L. Adams and Kate Burba
The novel interleukin 13 inhibitor lebrikizumab improved skin lesions, pruritis and quality of life among adults with moderate to severe atopic dermatitis, according to researchers from the Icahn School of Medicine at Mount Sinai and published in JAMA Dermatology. “There are two important findings from this study. First, [the results] provide a new treatment that is safe for atopic dermatitis patients and shows a hint that maybe it can be given every 4 weeks, which is important,” said Emma Guttman-Yassky, MD, PhD,professor of dermatology, medicine, and clinical immunology at the Icahn School of Medicine at Mount Sinai.
— Emma Guttman-Yassky, MD, PhD, Professor, Dermatology, Clinical Immunology, Medicine, Vice Chair, Research, Department of Dermatology, Director, The Center for Excellence in Eczema, Director, Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai
New Treatment for Moderate to Severe Atopic Dermatitis Shows Promising Long-Term ResultsDec 09, 2022 View All Press Releases